FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3201224866> ?p ?o ?g. }

• W3201224866 endingPage "103503" @default.
• W3201224866 startingPage "103503" @default.
• W3201224866 abstract "Cognitive decline leading to dementia, accompanied by the accumulation of amyloid-beta (Aβ) in neuritic plaques together with the appearance of neurofibrillary tangles (NFT) composed of hyperphosphorylated tau protein (tau), are previously noted hallmarks of Alzheimer's disease (AD). We previously discovered hypervascularity in brain specimens from AD patients and consistent with this observation, we demonstrated that overexpression of Aβ drives cerebrovascular neoangiogenesis leading to hypervascularity and coincident tight-junction disruption and blood-brain barrier (BBB) leakiness in animal models of AD. We subsequently demonstrated that amyloid plaque burden and cerebrovascular pathogenesis subside when pro-angiogenic Aβ levels are reduced. Based on these data, we propose a paradigm of AD etiology where, as a compensatory response to impaired cerebral blood flow (CBF), Aβ triggers pathogenic cerebrovascular neoangiogenesis that underlies the conventional hallmarks of AD. Consequently, here we present evidence that repurposing anti-cancer drugs to modulate cerebrovascular neoangiogenesis, rather than directly targeting the amyloid cascade, may provide an effective treatment for AD and related vascular diseases of the brain.We explored whether the anti-cancer drug, Axitinib, a small molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR) can inhibit aberrant cerebrovascular neoangiogenic changes, reduce Aβ deposits and reverse cognitive decline in an animal model of AD. One month post-treatment with Axitinib, we employed a battery of tests to assess cognition and memory in aged Tg2576 AD mice and used molecular analysis to demonstrate reduction of amyloid plaques, BBB leakage, hypervascularity and associated disease pathology.Targeting the pro-angiogenic pathway in AD using the cancer drug, Axitinib, dramatically reduced cerebrovascular neoangiogenesis, restored BBB integrity, resolved tight-junction pathogenesis, diminishes Aβ depositions in plaques and effectively restores memory and cognitive performance in a preclinical mouse model of AD.Modulation of neoangiogenesis, in an analogous approach to those used to treat aberrant vascularization in cancer and also in the wet form of age-related macular degeneration (AMD), provides an alternative therapeutic strategy for intervention in AD that warrants clinical investigation.None." @default.
• W3201224866 created "2021-09-27" @default.
• W3201224866 creator A5027510446 @default.
• W3201224866 creator A5035244694 @default.
• W3201224866 creator A5036969637 @default.
• W3201224866 creator A5054463576 @default.
• W3201224866 creator A5062222030 @default.
• W3201224866 creator A5091825430 @default.
• W3201224866 date "2021-09-01" @default.
• W3201224866 modified "2023-10-15" @default.
• W3201224866 title "Reversing pathology in a preclinical model of Alzheimer's disease by hacking cerebrovascular neoangiogenesis with advanced cancer therapeutics" @default.
• W3201224866 cites W1480745369 @default.
• W3201224866 cites W1556362327 @default.
• W3201224866 cites W1883306593 @default.
• W3201224866 cites W1963958884 @default.
• W3201224866 cites W1972850922 @default.
• W3201224866 cites W197484533 @default.
• W3201224866 cites W1981711337 @default.
• W3201224866 cites W1989839696 @default.
• W3201224866 cites W1990439587 @default.
• W3201224866 cites W1992759422 @default.
• W3201224866 cites W1994609866 @default.
• W3201224866 cites W2001210466 @default.
• W3201224866 cites W2002520289 @default.
• W3201224866 cites W2003991309 @default.
• W3201224866 cites W2006035554 @default.
• W3201224866 cites W2015469615 @default.
• W3201224866 cites W2021255508 @default.
• W3201224866 cites W2023952988 @default.
• W3201224866 cites W2025313184 @default.
• W3201224866 cites W2032984534 @default.
• W3201224866 cites W2034297743 @default.
• W3201224866 cites W2036661577 @default.
• W3201224866 cites W2040490831 @default.
• W3201224866 cites W2063038783 @default.
• W3201224866 cites W2073680876 @default.
• W3201224866 cites W2095613667 @default.
• W3201224866 cites W2096514095 @default.
• W3201224866 cites W2099495321 @default.
• W3201224866 cites W2106932520 @default.
• W3201224866 cites W2146249493 @default.
• W3201224866 cites W2152304945 @default.
• W3201224866 cites W2162294352 @default.
• W3201224866 cites W2169374397 @default.
• W3201224866 cites W2211673387 @default.
• W3201224866 cites W2412146432 @default.
• W3201224866 cites W2415637550 @default.
• W3201224866 cites W2498953078 @default.
• W3201224866 cites W2552609792 @default.
• W3201224866 cites W2610795807 @default.
• W3201224866 cites W2760907988 @default.
• W3201224866 cites W2820146740 @default.
• W3201224866 cites W2891966248 @default.
• W3201224866 cites W2896175597 @default.
• W3201224866 cites W2910508414 @default.
• W3201224866 cites W2911147760 @default.
• W3201224866 cites W2914003759 @default.
• W3201224866 cites W2918066696 @default.
• W3201224866 cites W2995183059 @default.
• W3201224866 cites W3095970076 @default.
• W3201224866 cites W4231337587 @default.
• W3201224866 cites W4327849154 @default.
• W3201224866 doi "https://doi.org/10.1016/j.ebiom.2021.103503" @default.
• W3201224866 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8449085" @default.
• W3201224866 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34534764" @default.
• W3201224866 hasPublicationYear "2021" @default.
• W3201224866 type Work @default.
• W3201224866 sameAs 3201224866 @default.
• W3201224866 citedByCount "13" @default.
• W3201224866 countsByYear W32012248662022 @default.
• W3201224866 countsByYear W32012248662023 @default.
• W3201224866 crossrefType "journal-article" @default.
• W3201224866 hasAuthorship W3201224866A5027510446 @default.
• W3201224866 hasAuthorship W3201224866A5035244694 @default.
• W3201224866 hasAuthorship W3201224866A5036969637 @default.
• W3201224866 hasAuthorship W3201224866A5054463576 @default.
• W3201224866 hasAuthorship W3201224866A5062222030 @default.
• W3201224866 hasAuthorship W3201224866A5091825430 @default.
• W3201224866 hasBestOaLocation W32012248662 @default.
• W3201224866 hasConcept C126322002 @default.
• W3201224866 hasConcept C142724271 @default.
• W3201224866 hasConcept C169760540 @default.
• W3201224866 hasConcept C2776156579 @default.
• W3201224866 hasConcept C2777790613 @default.
• W3201224866 hasConcept C2777952318 @default.
• W3201224866 hasConcept C2778402981 @default.
• W3201224866 hasConcept C2779134260 @default.
• W3201224866 hasConcept C2779483572 @default.
• W3201224866 hasConcept C2780192575 @default.
• W3201224866 hasConcept C2984863031 @default.
• W3201224866 hasConcept C502032728 @default.
• W3201224866 hasConcept C502942594 @default.
• W3201224866 hasConcept C529278444 @default.
• W3201224866 hasConcept C71924100 @default.
• W3201224866 hasConcept C86803240 @default.
• W3201224866 hasConcept C87753298 @default.
• W3201224866 hasConceptScore W3201224866C126322002 @default.
• W3201224866 hasConceptScore W3201224866C142724271 @default.

• next